TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetic Comparison of Co-administration and a Combination Drug of Rosuvastatin and Olmesartan in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers between the ages of 20 and 50 and within 20% of their ideal body weight, without congenital abnormality or chronic disease~Exclusion Criteria:~* History of cardiovascular, pulmonary, renal, endogenous, gastrointestinal, hematologic, neurologic or hemorrhagic disease;~* Clinically significant findings on routine laboratory (hematology, serum chemistry and urinalysis) or ECG tests;~* Use of prescription drugs in the 14 days immediately prior to starting the study that had the potential to interact with the study medication;~* Use of any substance that could induce or inhibit drug metabolism enzymes

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Test and reference formulations (Type: EXPERIMENTAL): Test formulation and reference formulation given orally 7 days apart in a fasted state

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of HPV Vaccine in Immunosuppressed Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Immunosuppressed patients with following diseases; Bone marrow transplant recipients, liver transplant patients, renal transplant, Children with inflammatory bowel disease, juvenile Idiopathic arthritis and autoimmune conditions.~Exclusion Criteria:~* A platelet count of \<50~* Immunoglobulin therapy within 3 months.~* Yeast allergy~* Any other known allergies to one of the vaccine component

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- HPV vaccine (Type: EXPERIMENTAL): Quadrivalent HPV vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-pulsed 1064 nm Nd-YAG Laser Versus TCA 20% in Treatment of Keratosis Pilaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients above 18 years with KP.~* Patients with KP affecting back of the trunk, arms, thighs, forearms, legs and buttocks.~Exclusion Criteria:~* Pregnant or lactating females.~* Patients who had performed any laser treatment for KP within 6 months prior to the study.~* Patients with history of oral retinoids within 3 months prior to the study.~* Patients with history of hypertrophic scars or keloids.~* Patients who used any topical treatment one month prior to the session.~* Patients with acne affecting the same sites of keratosis pilaris.~* Patients with active skin diseases affecting the area involved with KP e.g. folliculitis and eczema.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Nd-YAG laser (Type: ACTIVE_COMPARATOR): laser hair removal
- TCA 20% (Type: EXPERIMENTAL): chemical peel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alendronate Versus Denosumab in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult ≥ 18 year old and medically stable.~* Recent kidney transplantation (up to 3 months).~* Stabilization of renal allograft function.~* Normal liver function.~* Reduced bone mineral density at least one SD lower than normal level for the same age and gender (T-score \< -1).~Exclusion Criteria:~* Poor or unstable graft function (creatinine \>200 lmol/L).~* Skeletal malignancies or bone metastases.~* Risk for osteosarcoma, such as Paget's disease of the bone.~* Unstable medical condition.~* Pregnancy and lactation.~* Autoimmune diseases.~* Predisposition to drug hypersensitivity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): Participants will receive daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
- Denosumab group (Type: EXPERIMENTAL): Participants will receive a single 60 mg subcutaneous dose of denosumab (Prolia) every 6 months for 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
- Alendronate group (Type: EXPERIMENTAL): Participants will receive an oral alendronate at a dose of 70 mg once every week for up to 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Two-way Texting for VMMC Follow-up in Republic of South Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For VMMC clients:~1. are at least 18 years of age or over~2. Possession of own phone at enrollment~3. Willing to respond to daily text~4. Provides contact details (phone, address)~5. Undergoes surgical MC~6. Willing to follow NDoH VMMC protocols~7. No interoperative AE~8. Informed consent~9. Receives confirmed 2wT enrollment text.~Exclusion Criteria:~For VMMC clients:~1. Not meeting above requirements~2. Men without cell phones~3. Men who chose PrePex device-based VMMC~4. Inter-operative AE during VMMC~5. No informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Text-based VMMC follow-up (Type: EXPERIMENTAL): Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
- Routine VMMC follow-up care (Type: NO_INTERVENTION): Routine VMMC follow up care with in person visits according to national guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Preoperative Dexamethasone Study on QOL After Vaginal Reconstructive Surgery for POP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18-81 years old who are scheduled to undergo a major vaginal reconstructive surgery, including hysterectomy with or without hysterectomy~Exclusion Criteria:~* Daily use of steroids or antiemetic agents such as Zofran, Reglan, Compazine and Phenargan within one month of surgery~* Regional anesthesia for surgical procedure~* Chronic pain requiring opioid treatment daily~* History of allergy to the study medication~* Severe renal and liver disease~* Pregnancy~* Non English speaking~* Psychiatric disorder that will preclude completion of questionnaires~* Minor surgery that does not involve overnight admission~* Surgery that does not involve hysterectomy or vaginal intraperitoneal apical suspension~* Hypersensitivity reaction to steroids~* Evidence of systemic fungal infection~* Evidence of any systemic infection~* Uncontrolled diabetes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): Dexamethasone
- Placebo (Type: PLACEBO_COMPARATOR): Sterile normal saline solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants age is 18 years or older.~2. Participants have a moderate-to-severe rosacea excluding lesions involving the eyes and scalp.~3. Subject must have diagnosed rosacea for at least 6 months prior to screening.~Exclusion Criteria:~1. History of hypersensitivity or allergy to minocycline, any other tetracycline or any other component of the formulation such as Soybean oil or Coconut oil.~2. Women of child bearing potential who are pregnant, lactating (in the last 3 months) or planning to become pregnant during the study period.~3. Moderate or severe rhinophyma, dense telangiectasis (score 3, severe), or plaque- like facial edema.~4. Rosacea conglobata or fulminans, corticosteroid-induced rosacea or isolated pustulosis of the chin, facial erythrosis of known origin other than rosacea (e.g., known carcinoid syndrome).~5. Ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical ophthalmic or systemic antibiotics, papulopustular rosacea that requires medically indicated systemic treatment.~6. Bacterial folliculitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX-103 1.5% (Type: EXPERIMENTAL): The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
- FMX-103 3% (Type: EXPERIMENTAL): The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
- Vehicle foam (0%) (Type: PLACEBO_COMPARATOR): The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible if the following criteria are met:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Predominantly hemorrhagic subfoveal CNV (at least 50% of the lesion composed of hemorrhage) from age-related macular degeneration (AMD) resulting in visual acuity of 20/40 or worse.~* Age greater than 50 years.~* Participant must have media clear enough to permit fundus photography, fluorescein angiography, and optical coherence tomography.~Exclusion Criteria:~Subjects who meet any of the following criteria will be excluded from this study:~* Known hypersensitivity to humanized monoclonal antibodies~* History (within past 6 months) or evidence of severe cardiac disease (apparent in electrocardiogram abnormalities, clinical history of unstable angina, acute coronary syndrome, myocardial infarction, revascularization procedure within 6 months prior to baseline, atrial or ventricular tachyarrhythmias requiring ongoing treatment).~* History of stroke within 6 months of study entry.~* Current acute ocular or periocular infection.~* Any major surgical procedure within one month of study entry.~* Known serious allergies to fluorescein dye.~* Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, Protein Kinase C inhibitors, etc) within last 6 months.~* Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye within the last 6 months.~* History of subfoveal laser treatment in the study eye.~* History of other visually-limiting conditions such as optic neuropathy, amblyopia, choroidal neovascularization due to causes other than AMD in the study eye.~* Ocular inflammation (including trace or above) in the study eye.~* Inability to comply with study or follow up procedures.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 0.3 mg/0.05 ml dose of ranibizumab
- B (Type: EXPERIMENTAL): 0.5 mg/0.05 ml dose of ranibizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA detected at screening~* Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy~* Classification as treatment naïve or treatment experienced. Approximately 20% may be treatment-experienced.~* Cirrhosis determination (approximately 20% may have cirrhosis)~* Females of childbearing potential must have a negative urine pregnancy test at Screening and on Day 1 prior to enrollment.~* Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in the study protocol~* Lactating females must agree to discontinue nursing before the study drug is administered~* Adults must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments~Key Exclusion Criteria:~* Current or prior history of any of the following:~  * Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~ * Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)~ * Liver transplantation~ * Hepatocellular carcinoma (HCC) (as determined by appropriate imaging at screening for those with cirrhosis) or current malignancy for which the patient is receiving treatment or which may interfere with individual's treatment, assessment or compliance with the protocol.~* Screening laboratory parameters outside of defined threshold~* Prior exposure to HCV NS5A inhibitor~* Pregnant or nursing female~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Use of any prohibited concomitant medications as described in study protocol~* Known hypersensitivity to VEL, SOF, or formulation excipients~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Decrease Emergence Agitation and Provide Pain Relief for Children Undergoing Tonsillectomy & Adenoidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ages 2-10 ASA rating of I-III undergoing general anesthesia tonsillectomy with and without adenoidectomy~Exclusion Criteria:~* diagnosis of anxiety disorder or chronic pain syndrome chronic disabilities or developmental delays are currently on psychotherapeutic or sedating medication are on chronic pain medication or opiate any known adverse effect to the study drug any known cardiac abnormalities

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- fentanyl (Type: ACTIVE_COMPARATOR): fentanyl bolus 1ug.kg-1
- dexmedetomidine (Type: EXPERIMENTAL): dexmedetomidine 2ug.kg-1 over 10 min followed by 0.7ug.kg-1.h-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Administration of Vitamin C in Wrist Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* wrist fracture~* adult (18 years and older)~Exclusion Criteria:~* no comprehension of the written information~* not able to appear for follow-up (living abroad)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Different Omeprazole Dosing on Gastric pH in Non-variceal Upper Gastrointestinal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent must be obtained before any treatment or assessment is performed~* patients admitted with upper gastrointestinal bleeding (UGIB) symptoms to the Emergency Department of the University Hospital of Bialystok (Bialystok, Poland)~Exclusion Criteria:~* pregnancy~* age \>90 years~* lack of written consent~* recent treatment with certain medications, including PPIs, H2-receptor antagonists (H2RA), antacids, steroids, oral contraceptives, clopidogrel, prasugrel and clarithromycin~* the presence of variceal UGIB~* history of surgery of upper gastro-intestinal tract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- omeprazole infusion (OI) group (Type: ACTIVE_COMPARATOR): After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OI group is then treated with an 8-mg/h continuous i.v. infusion of OME for 72 h.
- omeprazole bolus (OB) group (Type: ACTIVE_COMPARATOR): After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OB group receives a 40-mg i.v. bolus of OME every 12 h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided informed consent prior to any study specific procedures~* Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID)~* Patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ECG)~* Current psychotic episode (schizophrenia exacerbation) \< 2 weeks duration at Visit 1~* Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS) total score ≥ 80 and ≤ 120~* CGI-S score ≥ 4~Exclusion Criteria:~* Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders~* Bipolar I and II disorder~* Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders~* DSM-IV-TR axis II disorder of sufficient severity to interfere with participation in this study~* Women who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine 3mg (Type: EXPERIMENTAL): Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
- Cariprazine 6mg (Type: EXPERIMENTAL): Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
- Aripiprazole 10mg (Type: ACTIVE_COMPARATOR): Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
- Placebo (Type: PLACEBO_COMPARATOR): Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete